ReviewProblemy endokrinologii2026
[Matrix metalloproteinases in pituitary adenoma invasiveness].
Review in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas (PA) are the most common lesions of hypothalamic-pituitary region. Clinical presentations of PA depend on both hormonal activity and tumor growth characteristics. Despite the fact that PA are mostly benign, they can grow invasively and mechanically affect adjacent structures. With invasive growth of PA, radical removal is difficult and associated with a higher risk of surgical complications. Pathogenesis of PA invasiveness is not fully understood. Tumor cell invasion depends on both intercellular interactions within the tumor and interaction with extracellular matrix components (ECM). Major factors that play an important role in these processes include matrix metalloproteinase (MMP) family and tissue inhibitors of matrix metalloproteinases (TIMPs). Two MMPs were mostly studied in PA - types 2 and 9. These molecules are of interest, as they participate in degradation of type IV collagen, which is a key component of the ECM in hypothalamic-pituitary region. This review discusses the general concept of PA invasiveness, the characteristics of MMPs, and research of the relationship between these molecules and PA invasiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.